Eight More Years: US Supreme Court Sinks Sandoz’ Hopes On Enbrel

Erelzi Biosimilar Etanercept Is Now Barred Until 2029 In The US

Sandoz’ arguments urging the US Supreme Court to review patent litigation around Amgen’s Enbrel have fallen on deaf ears, blocking a route to market for biosimilar etanercept until 2029 in the US.

Road Sign 2029
The decision blocks US etanercept biosimilars until 2029 • Source: Alamy

Sandoz has failed in its attempt to convince the US Supreme Court to review patent litigation with Amgen over its Enbrel (etanercept) biologic brand, blocking biosimilars from the market for a further eight years, until 2029.

Earlier this year, Sandoz had confirmed that it would be trying one last time to topple patents protecting Enbrel for...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.